OLD National Bancorp IN Buys 38,631 Shares of Novo Nordisk A/S $NVO

Key Points

• OLD National Bancorp IN raised its stake in Novo Nordisk by 317.8%, buying 38,631 shares to hold 50,785 shares worth about $2.58 million after the quarter.
• Late‑stage trial results show the oral semaglutide pill met its main goal in 10–17 year olds with type 2 diabetes, and Novo plans to seek U.S. approval, potentially expanding the drug’s pediatric label and strengthening its oral GLP‑1 franchise.
• Market reaction and analyst views are mixed: NVO is trading down (~1.6%), Citigroup trimmed its target, and the consensus from analysts is a Hold with an average target of $65.56 amid competitive concerns.

OLD National Bancorp IN raised its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 317.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 50,785 shares of the company's stock after acquiring an additional 38,631 shares during the period. OLD National Bancorp IN's holdings in Novo Nordisk A/S were worth $2,584,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. True Wealth Design LLC lifted its stake in Novo Nordisk A/S by 209.8% during the 3rd quarter. True Wealth Design LLC now owns 443 shares of the company's stock valued at $25,000 after acquiring an additional 300 shares in the last quarter. Guerra Advisors Inc bought a new position in shares of Novo Nordisk A/S in the third quarter valued at approximately $25,000. Strengthening Families & Communities LLC bought a new position in shares of Novo Nordisk A/S in the third quarter valued at approximately $30,000. WealthCollab LLC grew its holdings in shares of Novo Nordisk A/S by 93.5% in the fourth quarter. WealthCollab LLC now owns 538 shares of the company's stock valued at $27,000 after acquiring an additional 260 shares in the last quarter. Finally, American National Bank & Trust bought a new position in shares of Novo Nordisk A/S in the fourth quarter valued at approximately $28,000. 11.54% of the stock is currently owned by institutional investors.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Late‑stage trial: oral semaglutide met its main goal in a trial of 10–17 year olds with type 2 diabetes, supporting a planned U.S. approval push and expanding the drug’s potential label into pediatrics — a clear pipeline positive. Novo Nordisk's new weight-loss pill meets main goal in late-stage diabetes study
• Positive Sentiment: Regulatory/launch implication: company and press reports say Novo plans to seek approval for the oral semaglutide pill to treat younger patients — success here could broaden long‑term revenue and strengthen the oral GLP‑1 franchise. Novo Nordisk to Seek Approval for Pill to Treat Diabetes in Young Patients
• Neutral Sentiment: Market reaction note: coverage highlights that NVO has dipped more than broader markets today, reflecting investor caution despite the clinical win. Novo Nordisk (NVO) Sees a More Significant Dip Than Broader Market
• Neutral Sentiment: Industry context: broader longevity/GLP‑1 debate and sector capital flows are keeping large cap GLP‑1 names (including Novo) in focus but add volatility rather than immediate directional news. The Longevity Trade Is No Longer a Buzzword — It’s a $120 Billion Market
• Negative Sentiment: Analyst downgrade/target cut: Citigroup trimmed its price target for Novo (maintaining a Neutral rating), signaling lower near‑term expectations and contributing to selling pressure. NVO Stock Gets Cut to DKK 275 — Yet The Bigger Story Remains Intact
• Negative Sentiment: Competitive/strategy concerns: commentary questions whether the GLP‑1 “golden age” can continue for incumbents and flags intensifying competition — a negative for long‑term growth multiple assumptions. Novo Nordisk: Is The GLP‑1 Golden Age Already Behind It?
• Negative Sentiment: Distribution/competitive move: Eli Lilly’s expanding direct‑to‑consumer channels (e.g., LillyDirect partnerships) may intensify commercial competition for GLP‑1 products and distribution, a potential headwind for market share. Hims Stock Drops on LillyDirect Deal. Can It Be the Netflix of Pharma?

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Sanford C. Bernstein assumed coverage on Novo Nordisk A/S in a report on Wednesday, March 18th. They issued an "outperform" rating and a $175.00 target price for the company. Nordea Equity Research lowered Novo Nordisk A/S to a "hold" rating in a report on Tuesday, February 24th. Weiss Ratings cut Novo Nordisk A/S from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Wednesday. Morgan Stanley upgraded Novo Nordisk A/S from an "underweight" rating to an "equal weight" rating and set a $40.00 target price on the stock in a research note on Tuesday, March 3rd. Finally, Jefferies Financial Group upgraded Novo Nordisk A/S from an "underperform" rating to a "hold" rating in a research note on Thursday, February 12th. Four research analysts have rated the stock with a Buy rating, eighteen have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $65.56.

Novo Nordisk A/S Trading Down 1.6%

NYSE NVO opened at $38.54 on Friday. The stock has a market capitalization of $172.07 billion, a price-to-earnings ratio of 11.11, a PEG ratio of 9.32 and a beta of 0.73. Novo Nordisk A/S has a one year low of $35.12 and a one year high of $81.44. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.80 and a quick ratio of 0.57. The business's fifty day moving average is $39.30 and its 200-day moving average is $47.94.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its earnings results on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, topping analysts' consensus estimates of $0.90 by $0.11. The company had revenue of $12.43 billion for the quarter, compared to analysts' expectations of $11.97 billion. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%. Equities research analysts predict that Novo Nordisk A/S will post 3.34 EPS for the current year.

Novo Nordisk A/S Announces Dividend

The firm also recently announced a dividend, which was paid on Wednesday, April 8th. Stockholders of record on Monday, March 30th were paid a dividend of $1.2751 per share. This represents a dividend yield of 723.0%. The ex-dividend date was Monday, March 30th. Novo Nordisk A/S's payout ratio is presently 50.43%.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.